Department of Biotechnology, Dalian Medical University, Dalian 116044, China.
Clin Chim Acta. 2013 Aug 23;423:83-9. doi: 10.1016/j.cca.2013.04.018. Epub 2013 Apr 29.
Annexin A7 (Anxa7) is a member of the multigene annexin superfamily of Ca(2+)-regulated and phospholipid-binding proteins. Accumulated evidence indicates that the deregulation, loss of heterozygosity (LOH) and subcellular localization of Anxa7 are associated with the occurrence, invasion, metastasis and progression of a variety of cancers. Anxa7 appears to have a tumor-suppression role in glioblastoma, glioblastoma multiforme (GBM), melanoma and prostate cancer (CaP) but, controversially and interestingly, Anxa7 also appears to promote the development and malignancies of liver cancer, gastric cancer (GC), nasopharyngeal carcinoma (NPC), colorectal cancer (CRC) and breast cancer (BC). The associations between Anxa7 and malignant tumors as well as potential mechanisms of action are summarized and discussed in current review. Anxa7 has potential for use as a biomarker for the diagnosis, treatment and prognosis of certain tumors.
膜联蛋白 A7（Anxa7）是钙（Ca2+）调节和磷脂结合蛋白的多基因膜联蛋白超家族的成员。越来越多的证据表明，Anxa7 的失调、杂合性丢失（LOH）和亚细胞定位与多种癌症的发生、侵袭、转移和进展有关。Anxa7 似乎在胶质母细胞瘤、多形性胶质母细胞瘤（GBM）、黑色素瘤和前列腺癌（CaP）中具有肿瘤抑制作用，但有趣的是，有争议的是，Anxa7 似乎也促进了肝癌、胃癌（GC）、鼻咽癌（NPC）、结直肠癌（CRC）和乳腺癌（BC）的发展和恶性转化。目前的综述总结并讨论了 Anxa7 与恶性肿瘤之间的关联以及潜在的作用机制。Anxa7 有望作为某些肿瘤的诊断、治疗和预后的生物标志物。
